Management of polyomavirus-associated nephropathy in renal transplant recipients

Nature Reviews Nephrology

Volumn 8, Issue 7, 2012, Pages 390-402

  Kuypers, Dirk R J ^a  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; CIDOFOVIR; CIDOFOVIR 3 HEXADECYLOXYPROPYL ESTER; IMMUNOGLOBULIN; LEFLUNOMIDE; MANITIMUS; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NUCLEIC ACID; QUINOLINE DERIVED ANTIINFECTIVE AGENT;

ADJUVANT THERAPY; BK VIRUS; BK VIRUS INFECTION; DRUG DOSE REDUCTION; GRAFT FAILURE; GRAFT RECIPIENT; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY DISEASE; KIDNEY GRAFT; KIDNEY TRANSPLANTATION; NONHUMAN; PATHOGENESIS; POLYMERASE CHAIN REACTION; POLYOMAVIRUS ASSOCIATED NEPHROPATHY; PRIORITY JOURNAL; REVIEW; URINE CYTOLOGY; VIRUS REPLICATION;

ANTIVIRAL AGENTS; BK VIRUS; HUMANS; KIDNEY TRANSPLANTATION; POLYOMAVIRUS INFECTIONS; POSTOPERATIVE COMPLICATIONS; TUMOR VIRUS INFECTIONS;

EID: 84862886519     PISSN: 17595061     EISSN: 1759507X     Source Type: Journal    
DOI: 10.1038/nrneph.2012.64     Document Type: Review

References (126)

1. Dharnidharka, V. R., Cherikh, W. S. & Abbott, K. C. An OPTN analysis of national registry data on treatment of BK virus allograft nephropathy in the United States. Transplantation 87, 1019-1026 (2009).
2. Dharnidharka, V. R., Cherikh, W. S., Neff, R., Cheng, Y. & Abbott, K. C. Retransplantation after BK virus nephropathy in prior kidney transplant: an OPTN database analysis. Am. J. Transplant. 10, 1312-1315 (2010).
3. Smith, J. M., Dharnidharka, V. R., Talley, L., Martz, K. & McDonald, R. A. BK virus nephropathy in pediatric renal transplant recipients: an analysis of the North American Pediatric Renal Trials and Collaborative Studies (NAPRTCS) registry. Clin. J. Am. Soc. Nephrol. 2, 1037-1042 (2007).
4. Kidney Disease: Improving Global Outcomes (KDIGO) Transplant Workgroup. KDIGO clinical practice guideline for the care of kidney transplant recipients. Am. J. Transplant. 9, S1-S155 (2009).
5. United Network for Organ Sharing (UNOS) database. UNOS Data Request number 20111018-3. Based on OPTN data as of October 21, 2011. http://www.unos.org (2011).
6. Prince, O. et al. Risk factors for polyoma virus nephropathy. Nephrol. Dial. Transplant. 24, 1024-1033 (2009).
7. Schold, J. D. et al. Treatment for BK virus: incidence, risk factors and outcomes for kidney transplant recipients in the United States. Transpl. Int. 22, 626-634 (2009).
8. Busque, S. et al. Calcineurin-inhibitor-free immunosuppression based on the JAK inhibitor CP-690,550: a pilot study in de novo kidney allograft recipients. Am. J. Transplant. 9, 1936-1945 (2009).
9. Egli, A. et al. Prevalence of polyomavirus BK and JC infection and replication in 400 healthy blood donors. J. Infect. Dis. 199, 837-846 (2009).
10. Gosert, R. et al. Polyomavirus BK with rearranged noncoding control region emerge in vivo in renal transplant patients and increase viral replication and cytopathology. J. Exp. Med. 205, 841-852 (2008). (Pubitemid 351549882)
11. Olsen, G. H., Hirsch, H. H. & Rinaldo, C. H. Functional analysis of polyomavirus BK non-coding control region quasispecies from kidney transplant recipients. J. Med. Virol. 81, 1959-1967 (2009).
12. Perets, T. T. et al. High frequency and diversity of rearrangements in polyomavirus BK noncoding regulatory regions cloned from urine and plasma of Israeli renal transplant patients and evidence for a new genetic subtype. J. Clin. Microbiol. 47, 1402-1411 (2009).
13. Boldorini, R. et al. Genomic mutations of viral protein 1 and BK virus nephropathy in kidney transplant recipients. J. Med. Virol. 81, 1385-1393 (2009).
14. Tremolada, S. et al. Mutations in the external loops of BK virus VP1 and urine viral load in renal transplant recipients. J. Cell. Physiol. 222, 195-199 (2010).
15. Jiang, M., Abend, J. R., Tsai, B. & Imperiale, M. J. Early events during BK virus entry and disassembly. J. Virol. 83, 1350-1358 (2009).
16. Funk, G. A., Gosert, R., Comoli, P., Ginevri, F. & Hirsch, H. H. Polyomavirus BK replication dynamics in vivo and in silico to predict cytopathology and viral clearance in kidney transplants. Am. J. Transplant. 8, 2368-2377 (2008).
17. Abend, J. R. & Imperiale, M. J. Transforming growth factor-beta-mediated regulation of BK virus gene expression. Virology 378, 6-12 (2008).
18. Sadeghi, M. et al. Urinary proinflammatory cytokine response in renal transplant recipients with polyomavirus BK viruria. Transplantation 88, 1109-1116 (2009).
19. Hariharan, S. et al. BK virus-specific antibodies and BKV DNA in renal transplant recipients with nephritis. Am. J. Transplant. 5, 2719-2724 (2005).
20. Bohl, D. L. et al. BK virus antibody titers and intensity of infections after renal transplantation. J. Clin. Virol. 43, 184-189 (2008).
21. Randhawa, P. et al. Longitudinal analysis of levels of immunoglobulins against BK virus capsid proteins in kidney transplant recipients. Clin. Vaccine Immunol. 15, 1564-1571 (2008).
22. Bohl, D. L. et al. Donor origin of BK virus in renal transplantation and role of HLA C7 in susceptibility to sustained BK viremia. Am. J. Transplant. 5, 2213-2221 (2005). (Pubitemid 41648468)
23. Binggeli, S. et al. Polyomavirus BK-specific cellular immune response to VP1 and large T-antigen in kidney transplant recipients. Am. J. Transplant. 7, 1131-1139 (2007). (Pubitemid 46643106)
24. Zhou, W. et al. Functional characterization of BK virus-specific CD4+ T cells with cytotoxic potential in seropositive adults. Viral. Immunol. 20, 379-388 (2007). (Pubitemid 47585319)
25. Ginevri, F. et al. Prospective monitoring of polyomavirus BK replication and impact of pre-emptive intervention in pediatric kidney recipients. Am. J. Transplant. 7, 2727-2735 (2007). (Pubitemid 350045762)
26. Prosser, S. E., Orentas, R. J., Jurgens, L., Cohen, E. P. & Hariharan, S. Recovery of BK virus large T-antigen-specific cellular immune response correlates with resolution of BK virus nephritis. Transplantation 85, 185-192 (2008). (Pubitemid 351156848)
27. Mueller, K. et al. BK-VP3 as a new target of cellular immunity in BK virus infection. Transplantation 91, 100-107 (2011).
28. Schachtner, T. et al. BKV-specific immunity kinetics: a predictor of recovery from polyomavirus BK-associated nephropathy. Am. J. Transplant. 11, 2443-2452 (2011).
29. Womer, K. L. et al. Dendritic cell deficiency associated with development of BK viremia and nephropathy in renal transplant recipients. Transplantation 89, 115-123 (2010).
30. Babel, N., Volk, H. D. & Reinke, P. BK polyomavirus infection and nephropathy: the virus-immune system interplay. Nat. Rev. Nephrol. 7, 399-406 (2011).
31. Drachenberg, C. B. et al. Histological patterns of polyomavirus nephropathy: correlation with graft outcome and viral load. Am. J. Transplant. 4, 2082-2092 (2004). (Pubitemid 39611638)
32. Hirsh, H. H., Randhawa, P. & the AST Infectious Diseases Community of Practice. BK virus in solid organ transplant recipients. Am. J. Transplant. 9 (Suppl. 4), S136-S146 (2009).
33. Sis, B. et al. Banff '09 meeting report: antibody mediated graft deterioration and implementation of Banff working groups. Am. J. Transplant. 10, 464-471 (2010).
34. Renoult, E. et al. Evaluation of a preemptive strategy for BK polyomavirus-associated nephropathy based on prospective monitoring of BK viremia: a kidney transplantation center experience. Transplant. Proc. 42, 4083-4087 (2010).
35. Hoffman, N. G., Cook, L., Atienza, E. E., Limaye, A. P. & Jerome, K. R. Marked variability of BK virus load measurement using quantitative real-time PCR among commonly used assays. J. Clin. Microbiol. 46, 2671-2680 (2008).
36. Bechert, C. J., Schnadig, V. J., Payne, D. A. & Dong, J. Monitoring of BK viral load in renal allograft recipients by real-time PCR assays. Am. J. Clin. Pathol. 133, 242-250 (2010).
37. Hirsch, H. H. et al. Polyomavirus-associated nephropathy in renal transplantation: interdisciplinary analysis and recommendations. Transplantation 79, 1277-1286 (2005). (Pubitemid 40734783)
38. Pang, X. L., Doucette, K., LeBlanc, B., Cockfield, S. M. & Preiksaitis, J. K. Monitoring of polyomavirus BK virus viruria and viremia in renal allograft recipients by use of a quantitative real-time PCR assay: one-year prospective study. J. Clin. Microbiol. 45, 3568-3573 (2007). (Pubitemid 350156850)
39. Viscount, H. B. et al. Polyomavirus polymerase chain reaction as a surrogate marker of polyomavirus-associated nephropathy. Transplantation 84, 340-345 (2007). (Pubitemid 47258321)
40. Costa, C. et al. Monitoring of BK virus replication in the first year following renal transplantation. Nephrol. Dial. Transplant. 23, 3333-3336 (2008).
41. Sung, H., Choi, B. H., Pyo, Y. J., Kim, M. N. & Han, D. J. Quantitation of BK virus DNA for diagnosis of BK virus-associated nephropathy in renal transplant recipients. J. Korean Med. Sci. 23, 814-818 (2008).
42. Boudreault, A. A. et al. Screening for polyomavirus associated nephropathy in renal transplantation with blood viral load measurement. J. Clin. Virol. 45, 318-321 (2009).
43. Laskin, B. L. & Goebel, J. Cost-efficient screening for BK virus in pediatric kidney transplantation: a single-center experience and review of the literature. Pediatr. Transplant. 14, 589-595 (2010).
44. Pollara, C. P. et al. Quantitative viral load measurement for BKV infection in renal transplant recipients as a predictive tool for BKVAN. New Microbiol. 34, 165-171 (2011).
45. Dadhania, D. et al. Validation of noninvasive diagnosis of BK virus nephropathy and identification of prognostic biomarkers. Transplantation 90, 189-197 (2010).
46. Bergallo, M. et al. Real-time RT-PCR assay for the quantitation of polyomavirus BK VP1 mRNA levels in urine. Mol. Biotechnol. 45, 82-86 (2010).
47. Chakera, A. et al. Detection of polyomavirus BK reactivation after renal transplantation using an intensive decoy cell surveillance program is cost-effective. Transplantation 92, 1018-1023 (2011).
48. Koukoulaki, M. et al. Prospective study of urine cytology screening for BK polyoma virus replication in renal transplant recipients. Cytopathology 19, 385-388 (2008).
49. Maia, T. M. et al. Polyomavirus-infected decoy cells in cytocentrifuged urine cytology specimens from renal transplant recipients. Acta Cytol. 55, 445-448 (2011).
50. Babel, N. et al. Sustained BK viruria as an early marker for the development of BKV-associated nephropathy: analysis of 4128 urine and serum samples. Transplantation 88, 89-95 (2009).
51. Koukoulaki, M. et al. Prospective monitoring of BK virus replication in renal transplant recipients. Transpl. Infect. Dis. 11, 1-10 (2009).
52. Smith, F., Panek, R. & Kiberd, B. A. Screening to prevent polyoma virus nephropathy in kidney transplantation: a cost analysis. Am. J. Transplant. 9, 2177-2179 (2009).
53. Singh, H. K. et al. Presence of urinary Haufen accurately predicts polyomavirus nephropathy. J. Am. Soc. Nephrol. 20, 416-427 (2009).
54. Bennett, W. M., Meyer, L., Ridenour, J. & Batiuk, T. D. Surveillance and modification of immunosuppression minimizes BK virus nephropathy. Am. J. Nephrol. 32, 10-12 (2010).
55. Batal, I. et al. Measurements of global cell-mediated immunity in renal transplant recipients with BK virus reactivation. Am. J. Clin. Pathol. 129, 587-591 (2008). (Pubitemid 352029278)
56. Helanterä, I. & Koskinen, P. Association of immune cell function assay with protocol biopsy findings and viral infections in well matched kidney transplant recipients. Clin. Nephrol. 74, 123-131 (2010).
57. Johnston, O. et al. Treatment of polyomavirus infection in kidney transplant recipients: a systematic review. Transplantation 89, 1057-1070 (2010).
58. Brennan, D. C. et al. Incidence of BK with tacrolimus versus cyclosporine and impact of preemptive immunosuppression reduction. Am. J. Transplant. 5, 582-594 (2005). (Pubitemid 40313351)
59. Hardinger, K. L., Koch, M. J., Bohl, D. J., Storch, G. A. & Brennan, D. C. BK-virus and the impact of pre-emptive immunosuppression reduction: 5-year results. Am. J. Transplant. 10, 407-415 (2010).
60. Alméras, C. et al. Does reduction in immunosuppression in viremic patients prevent BK virus nephropathy in de novo renal transplant recipients? A prospective study. Transplantation 85, 1099-1104 (2008). (Pubitemid 351590186)
61. Alméras, C. et al. Monthly screening for BK viremia is an effective strategy to prevent BK virus nephropathy in renal transplant recipients. Transpl. Infect. Dis. 13, 101-108 (2011).
62. Schaub, S. et al. Reducing immunosuppression preserves allograft function in presumptive and definitive polyomavirus-associated nephropathy. Am. J. Transplant. 10, 2615-2623 (2010).
63. Hirsch, H. H. et al. Prospective study of polyomavirus type BK replication and nephropathy in renal-transplant recipients. N. Engl. J. Med. 347, 488-496 (2002). (Pubitemid 34879336)
64. Ramos, E. et al. Clinical course of polyoma virus nephropathy in 67 renal transplant patients. J. Am. Soc. Nephrol. 13, 2145-2151 (2002). (Pubitemid 34790793)
65. Vasudev, B. et al. BK virus nephritis, risk factors, timing, and outcome in renal transplant recipients. Kidney Int. 68, 1834-1839 (2005). (Pubitemid 43169929)
66. Randhawa, P. S. et al. Human polyoma virus-associated interstitial nephritis in the allograft kidney. Transplantation 67, 103-109 (1999). (Pubitemid 29061146)
67. Celik, B., Shapiro, R., Vats, A. & Randhawa, P. S. Polyomavirus allograft nephropathy: sequential assessment of histologic viral load, tubulitis, and graft function following changes in immunosuppression. Am. J. Transplant. 3, 1378-1382 (2003). (Pubitemid 37288082)
68. Saad, E. R. et al. Successful treatment of BK viremia using reduction in immunosuppression without antiviral therapy. Transplantation 85, 850-854 (2008). (Pubitemid 351440750)
69. Weiss, A. S., Gralla, J., Chan, L., Klem, P. & Wiseman, A. C. Aggressive immunosuppression minimization reduces graft loss following diagnosis of BK virus-associated nephropathy: a comparison of two reduction strategies. Clin. J. Am. Soc. Nephrol. 3, 1812-1819 (2008).
70. Kotton, C. N. et al. International consensus guidelines on the management of cytomegalovirus in solid organ transplantation. Transplantation 89, 779-795 (2010).
71. Manitpisitkul, W. et al. Maintenance immunosuppressive agents as risk factors for BK virus nephropathy: a case-control study. Transplantation 88, 83-88 (2009).
72. Kuypers, D. R., Bammens, B., Claes, K., Evenepoel, P. & Vanrenterghem, Y. Maintenance immunosuppressive agents as risk factors for BK virus nephropathy: the need for true drug exposure measurements. Transplantation 89, 1296-1297 (2010).
73. Geddes, C. C. et al. BK viremia surveillance after kidney transplant: single-center experience during a change from cyclosporine-to lower-dose tacrolimus-based primary. Transpl. Infect. Dis. 13, 109-116 (2011).
74. Suwelack, B., Malyar, V., Koch, M., Sester, M. & Sommerer, C. The influence of immunosuppressive agents on BK virus risk following kidney transplantation, and implications for choice of regimen. Transplant. Rev. (Orlando) http://dx.doi.org/10.1016/j.trre.2011.05.002.
75. Cooper, J. E., Huskey, J., Chan, L. & Wiseman, A. C. Preemptive retransplant for BK virus nephropathy without concurrent transplant nephrectomy. Transplantation 90, 331-332 (2010).
76. Womer, K. L., Patton, P. R. & Kaplan, B. Aggressive post-transplant monitoring of more importance to successful outcome following re-transplantation for BK virus nephropathy than absence of pretransplant viremia. Transpl. Int. 21, 1103-1104 (2008).
77. Hirsh, H. H. & Ramos, E. Retransplantation after polyomavirus- associated nephropathy: just do it? Am. J. Transplant. 6, 7-9 (2006). (Pubitemid 43382193)
78. Bernhoff, E., Gutteberg, T. J., Sandvik, K., Hirsch, H. H. & Rinaldo, C. H. Cidofovir inhibits polyomavirus BK replication in human renal tubular cells downstream of viral early gene expression. Am. J. Transplant. 8, 1413-1422 (2008). (Pubitemid 351989495)
79. Topalis, D., Lebeau, I., Krecmerova, M., Andrei, G. & Snoeck, R. Activities of different classes of acyclic nucleoside phosphonates against BK virus in primary human renal cells. Antimicrob. Agents Chemother. 55, 1961-1967 (2011).
80. Randhawa, P., Farasati, N. A., Shapiro, R. & Hostetler, K. Y. Ether lipid ester derivates of cidofovir inhibit polyomavirus BK replication in vitro. Antimicrob. Agents Chemother. 50, 1564-1566 (2006).
81. Rinaldo, C. H., Gosert, R., Bernhoff, E., Finstad, S. & Hirsch, H. H. 1-O-hexadecycloxypropyl cidofovir (CMX001) effectively inhibits polyomavirus BK replication in primary human renal tubular epithelial cells. Antimicrob. Agents Chemother. 54, 4714-4722 (2010).
82. Hostetler, K. Y. Alkoxyalkyl prodrugs of acyclic nucleoside phosphonates enhance oral antiviral activity and reduce toxicity: current state of the art. Antiviral Res. 82, A84-A98 (2009).
83. US National Library of Medicine. ClinicalTrials.gov [online], http://clinicaltrials.gov/ct2/show/NCT00793598 (2011).
84. Bernhoff, E. et al. Leflunomide inhibition of BK virus replication in renal tubular epithelial cells. J. Virol. 84, 2150-2156 (2010).
85. Canivet, C. et al. Polyoma BK virus-associated nephropathy in kidney-transplant patients: effects of leflunomide on T-cell functions and disease outcome. Int. Immunopharmacol. 9, 1131-1136 (2009).
86. Liacini, A., Seamone, M. E., Muruve, D. A. & Tibbles, L. A. Anti-BK virus mechanisms of sirolimus and leflunomide alone and in combination: toward a new therapy for BK virus infection. Transplantation 90, 1450-1457 (2010).
87. Farasati, N. A. et al. Effect of leflunomide and cidofovir on replication of BK virus in an in vitro culture system. Transplantation 79, 116-118 (2005). (Pubitemid 40140009)
88. Waldman, W. J. et al. Inhibition of cytomegalovirus in vitro and in vivo by the experimental immunosuppressive agent leflunomide. Intervirology 42, 412-418 (1999). (Pubitemid 30122078)
89. Sharma, B. N., Li, R., Bernhoff, E., Gutteberg, T. J. & Rinaldo, C. H. Fluoroquinolones inhibit human polyomavirus BK (BKV) replication in primary human kidney cells. Antiviral Res. 92, 115-123 (2011).
90. Ali, S. H., Chandraker, A. & DeCaprio, J. A. Inhibition of Simian virus large T antigen helicase activity by fluoroquinolones. Antivir. Ther. 12, 1-6 (2007). (Pubitemid 46340419)
91. Cuesta, I. et al. Conformational rearrangements of SV40 large T antigen during early replication events. J. Mol. Biol. 397, 1276-1286 (2010).
92. Israel, D. et al. Pharmacokinetics and serum bactericidal titers of ciprofloxacin and ofloxacin following multiple oral doses in healthy volunteers. Antimicrob. Agents Chemother. 37, 2193-2199 (1993). (Pubitemid 23298210)
93. Landersdorfer, C. B. et al. Competitive inhibition of renal tubular secretion of ciprofloxacin and metabolite by probenecid. Br. J. Clin. Pharmacol. 69, 167-178 (2010).
94. Masereeuw, R. & Russel, F. G. Therapeutic implications of renal anionic drug transporters. Pharmacol. Ther. 126, 200-216 (2010).
95. Randhawa, P. S. Anti-BK virus activity of ciprofloxacin and related antibiotics. Clin. Infect. Dis. 41, 1366-1367 (2005). (Pubitemid 41532690)
96. Randhawa, P. S., Schonder, K., Shapiro, R., Farasati, N. & Huang, Y. Polyomavirus BK neutralizing activity in human immunoglobulin preparations. Transplantation 89, 1462-1465 (2010).
97. Randhawa, P. S., Farasati, N. A., Huang, Y., Mapara, M. Y. & Shapiro, R. Viral drug sensitivity testing using quantitative PCR: effect of tyrosine kinase inhibitors on polyomavirus BK replication. Am. J. Clin. Pathol. 134, 916-920 (2010).
98. Acott, P., O'Regan, P. A. & Crocker, J. F. Supression of early and chronic BK polyoma virus replication by mycophenolic acid in Vero cells. Transpl. Int. 22, 225-231 (2009).
99. Acott, P. D., O'Regan, P. A., Lee, S. H. & Crocker, J. F. In vitro effect of cyclosporine A on primary and chronic BK polyoma virus infection in Vero E6 cells. Transpl. Infect. Dis. 10, 385-390 (2008).
100. Li, Y. J. et al. A suppressive effect of cyclosporine A on replication and noncoding control region activation of polyomavirus BK virus. Transplantation 89, 299-306 (2010).
101. Tikhanovich, I., Liang, B., Seoighe, C., Folk, W. R. & Nasheuer, H. P. Inhibition of human BK polyomavirus replication by small noncoding RNAs. J. Virol. 85, 6930-6940 (2011).
102. Egli, A., Köhli, S., Dickenmann, M. & Hirsch, H. H. Inhibition of polyomavirus BK-specific T-cell responses by immunosuppressive drugs. Transplantation 88, 1161-1168 (2009).
103. Hilton, R. & Tong, C. Y. Antiviral therapy for polyomavirus- associated nephropathy after renal transplantation. J. Antimicrob. Chemother. 62, 855-859 (2008).
104. Tong, C. Y. et al. Monitoring the progress of BK virus associated nephropathy in renal transplant recipients. Nephrol. Dial. Transplant. 19, 2598-2605 (2004). (Pubitemid 39360110)
105. Burgos, D. et al. Polyomavirus BK nephropathy: the effect of an early diagnosis on renal function or graft loss. Transplant. Proc. 38, 2409-2411 (2006). (Pubitemid 44693685)
106. Wadei, H. M. et al. Kidney transplant function and histological clearance of virus following diagnosis of polyomavirus-associated nephropathy (PVAN). Am. J. Transplant. 6, 1025-1032 (2006). (Pubitemid 44356654)
107. Benavides, C. A. et al. BK virus-associated nephropathy in sirolimus-treated renal transplantpatients: incidence, course, and clinical outcomes. Transplantation 84, 83-88 (2007). (Pubitemid 47094646)
108. Kuypers, D. R. et al. Adjuvant low-dose cidofovir therapy for BK polyomavirus interstitial nephritis in renal transplant recipients. Am. J. Transplant. 5, 1997-2004 (2005). (Pubitemid 41039877)
109. Wu, S. W., Chang, H. R. & Lian, J. D. The effect of low-dose cidofovir on the long-term outcome of polyomavirus-associated nephropathy in renal transplant recipients. Nephrol. Dial. Transplant. 24, 1034-1038 (2009).
110. Kuypers, D. R. et al. A single-centre study of adjuvant cidofovir therapy for BK virus interstitial nephritis (BKVIN) in renal allograft recipients. J. Antimicrob. Chemother. 63, 417-419 (2009).
111. Cundy, K. C. et al. Clinical pharmacokinetics of cidofovir in human immunodeficiency virus-infected patients. Antimicrob. Agents Chemother. 39, 1247-1252 (1995).
112. Araya, C. E., Lew, J. F., Fennell, R. S., Neiberger, R. E. & Dharnidharja, V. R. Intermediate dose cidofovir does not cause additive nephrotoxicity in BK virus allograft nephropathy. Pediatr. Transplant. 12, 790-795 (2008).
113. Cundy, K. C. Clinical pharmacokinetics of the antiviral nucleotide analogues cidofovir and adefovir. Clin. Pharmacokinet. 36, 127-143 (1999). (Pubitemid 29121686)
114. Uwai, Y., Ida, H., Tsuji, Y., Katsura, T. & Inui, K. Renal transport of adefovir, cidofovir and tenofovir by SLC22A family members (hOAT1, hOAT3, hOCT2). Pharmaceut. Res. 24, 811-815 (2007). (Pubitemid 46411965)
115. Imaoka, T. et al. Functional involvement of multidrug resistance-associated protein 4 (MRP4/ABCC4) in the renal elimination of the antiviral drugs adefovir and tenofovir. Mol. Pharmacol. 71, 619-627 (2007). (Pubitemid 46147926)
116. Hua, D. K., Howard, K., Craig, J. C., Chapman, J. R. & Wong, G. Cost-effectiveness of cidofovir treatment of polyomavirus nephropathy in kidney transplant recipients. Transplantation 93, 188-194 (2012).
117. Josephson, M. A. et al. Treatment of renal allograft polyoma BK virus infection with leflunomide. Transplantation 81, 704-710 (2006).
118. Faguar, S. et al. Leflunomide treatment for polyomavirus BK-associated nephropathy after kidney transplantation. Transpl. Int. 20, 962-969 (2007).
119. Leca, N. et al. Higher levels of leflunomide are associated with hemolysis and are not superior to lower levels for BK virus clearance in renal transplant patients. Clin. J. Am. Soc. Nephrol. 3, 829-835 (2008).
120. Teschner, S. et al. Leflunomide therapy for polyomavirus-induced allograft nephropathy: efficient BK virus elimination without increased risk of rejection. Transplant. Proc. 41, 2533-2538 (2009).
121. Chan, V., Charles, B. G. & Tett, S. E. Population pharmacokinetics and association between A77 1726 plasma concentrations and disease activity measures following administration of leflunomide to people with rheumatoid arthritis. Br. J. Clin. Pharmacol. 60, 257-264 (2005). (Pubitemid 41224133)
122. Guasch, A. et al. for the FK778 BK Nephropathy Study Group. Assessment of efficacy and safety of FK778 in comparison with standard care in renal transplant recipients with untreated BK nephropathy. Transplantation 90, 891-897 (2010).
123. Leung, A. Y. et al. Ciprofloxacin decreased polyoma BK virus load in patients who underwent allogeneic hematopoietic stem cell transplantation. Clin. Infect. Dis. 40, 528-537 (2005). (Pubitemid 40270222)
124. Koukoulaki, M., Apostolou, T., Hadjiconstantinou, V. & Drakopoulos, S. Impact of prophylactic administration of ciprofloxacin on BK polyoma virus replication. Transpl. Infect. Dis. 10, 449-451 (2008).
125. Gabardi, S. et al. Evaluation of fluoroquinolones for the prevention of BK viremia after renal transplantation. Clin. Am. J. Soc. Nephrol. 5, 1298-1304 (2010).
126. Sener, A. et al. Intravenous immunoglobulin as a treatment for BK virus associated nephropathy: one-year follow-up of renal allograft recipients. Transplantation 81, 117-120 (2006). (Pubitemid 43122158)